Drug Profile
Levofloxacin occular implant - PolyActiva
Alternative Names: Endophthalmitis preventive implant - PolyActivaLatest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator PolyActiva
- Class Anti-infectives; Anti-inflammatories; Eye disorder therapies; Fluoroquinolones; Small molecules
- Mechanism of Action DNA gyrase inhibitors; DNA topoisomerase IV inhibitors; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cataracts; Endophthalmitis
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for phase-I development in Cataracts in Australia (Intraocular, Implant)
- 28 Feb 2024 No recent reports of development identified for phase-I development in Cataracts in USA (Intraocular, Implant)
- 27 Mar 2023 PolyActiva suspends a phase I trial in cataracts in the USA and Australia prior to enrollment to conserve capital for clinical development of lead asset (Intraocular) (NCT05441930)